Prevalence of Aspirin Prescriptions among Type 2 Diabetic Patients in Songklanagarind Hospital

Rattanaporn Chootong, M.D.*, Silom Jamulitrat, M.D.

Department of Community Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.
*E-mail: e_oo_rad@hotmail.com
Songkla Med J 2018;36(1):35-44

Abstract:

Objective: The American Diabetes Association (ADA) and the American Heart Association (AHA) recommend aspirin use for primary and secondary prevention of cardiovascular disease in patients with diabetes. There are, however, some doubts regarding the prescription of aspirin therapy to prevent cardiovascular events in diabetic patients, aspects of its safety, and contraindications of the drug administration. This study was conducted in order to evaluate the amount of prescribed aspirin for diabetic patients who received the treatment at Songklanagarind Hospital.

Material and Method: A cross-sectional study was conducted to review the medical records of diabetic patients who received the treatment at outpatient departments from 1st-31st December 2013.

Results: A total of 1,342 diabetic patients are included in this study: 80.3% from the primary prevention group and 19.7% from the secondary prevention group. Mean age was 64.3 years old. Of the patients, 44.7% were male. The study revealed that prescribed aspirin accounted for one-third of total prescriptions (31.7%). The primary prevention group was 19.0% (95% confidence interval (CI)=12.0–21.3) and the secondary prevention group was 83.7% (95% CI=78.6–87.9). The departments that frequently prescribed aspirin for the primary prevention group was endocrinology (21.2%) and for the secondary prevention group it was the Primary Care Unit (87.5%). Aspirin side effects were gastrointestinal 1.0% and tinnitus 0.1%. Aspirin contraindications were active peptic ulcer (0.1%), history of gastrointestinal bleeding (0.4%), bleeding disorders (0.2%), history of recent intracranial bleeding (0.2%) and severe liver disease (0.9%). There was a positive correlation between age, hemoglobin A1c (HbA1c) and the dose of prescribed aspirin (p-value<0.001, 0.003 respectively). These patients were more likely to have the dose of aspirin increased as age and HbA1c increased.

Received 15 December 2016  Accepted 3 July 2017
Conclusion: Despite aspirin being a safe, inexpensive and readily available therapy that is effective in preventing cardiovascular disease in diabetic patients and likely to provide benefits rather than side effects and contraindications. The author found significant underuse of aspirin therapy, especially in the primary prevention of cardiovascular disease in diabetic patients.

Keywords: aspirin, contraindications, diabetes mellitus, diabetes mellitus type 2, side effects

Introduction

Diabetes mellitus (DM) has been a chronic disease affecting the health of people in Thailand and globally for a long time. Moreover, DM has globally increased morbidities, the mortality rate and economic losses such as costs of medical treatment, absences from work, etc. Cardiovascular disease (CVD) and chronic complications are the most common causes of death in patients with diabetes mellitus.1,2 Patients with diabetes have a 2–4-fold increased risk of cardiovascular events compared with age and sex matched individuals without diabetes.3

Aspirin is a salicylate nonsteroidal anti-inflammatory drugs (NSAIDs). Although originally used as a pain reliever and fever reducer, many studies have shown that aspirin can reduce the risks of cardiovascular diseases, such as atherosclerotic coronary heart disease, cerebrovascular disease and peripheral arterial disease. One of the effects of aspirin is to inhibit enzyme cyclo-oxygenase resulting in the direct inhibition of the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. Thus inhibiting platelet aggregation can reduce the causes of cardiovascular disease.

Research has shown that aspirin therapy is effective for primary prevention in diabetic patients (preventing a first heart attack, stroke or peripheral arterial disease).4,5 The Fremantle Diabetes Study7 observed that the administration of aspirin (≥75 mg/day) with a total follow-up period of 7,537 patient-years in patients with type 2 diabetes and no prior history of CVD association led to a reduction of CVD and all-cause mortality of at least 50.0%. For secondary prevention,6,7 aspirin has also been reported to significantly decrease the risks of future events in diabetic patients with previous myocardial infarction, stroke, transient cerebral ischemia or peripheral vascular disease.

The American Diabetes Association (ADA)8 and the American Heart Association (AHA)9 recommend aspirin for both primary and secondary prevention. Aspirin is recommended for primary prevention in adults with diabetes who have an increased risk of cardiovascular disease (10-year risk ≥10%) (75–162 mg/day) including men aged over 50 years and women over 60 who possess at least one additional risk factor (family history of CVD, hypertension, smoking, dyslipidemia or albuminuria). Aspirin therapy (75–162 mg/day) is recommended as a secondary prevention strategy in patients with diabetes and a history of CVD.

Although there is a guideline recommendation for the use of aspirin in patients with diabetes, several studies have found that the prevalence of aspirin prescription is considerably low,10,11 for example the BMC10 Family Practice Journal 2007 found that 20.8% of aspirin was prescribed routinely in the primary prevention group and 60.8% in the secondary prevention group.

Despite the benefits of aspirin, its side effects12–16 are also frequently found such as gastrointestinal (GI)
bleeding, tinnitus, hypersensitivities including bronchospasm, rhinitis, urticaria, angioedema and anaphylaxis or hepatic side effects including hepatotoxicity and cholestatic hepatitis.

Furthermore, there are also the contraindications of aspirin use such as active peptic ulcer, history of previous GI or intracranial bleeding, aspirin allergy or intolerance and bleeding disorders: hemophilia, Von Willebrand disease (VWD), thrombocytopenia or severe liver disease.

However, there have been very few studies on aspirin prescriptions in diabetic patients conducted in Thailand. Therefore, the rationale for the study was developed to investigate the prevalence of aspirin prescriptions, the frequency of adverse effects and contraindications of aspirin in diabetic patients who received the treatment at the outpatient departments of Songkla-nagarind Hospital, to measure the size of problems, to see whether the practice guidelines for diabetes treatment follow the standard guidelines provided, and lastly to develop future medical treatment for these patients.

**Material and Method**

**Research methodology**

This study is a cross-sectional study with retrospective medical review.

**Study population**

The population was type 2 diabetic patients who were followed up regularly at outpatient clinics at Songkla-nagarind Hospital. The sample in this study was type 2 diabetic patients who were followed up regularly and received diabetes treatment at the primary care unit, internal medicine clinic, endocrinology clinic, cardiovascular clinic, general practice clinic and surgery clinic from 1\textsuperscript{st}–31\textsuperscript{st} December 2013. Retrospective analysis of diabetes records was performed consecutively. Exclusion criteria were patients diagnosed with other types of diabetes mellitus (type 1, gestational diabetes mellitus (GDM) and other specific types); consequently routine diabetes care visits would not be performed.

**Study variables**

The variables included in this study are demographic data: age, sex, bodyweight, body mass index (BMI), systolic blood pressure, diastolic blood pressure and health insurance. Laboratory investigations consisted of serum fasting blood glucose (FBS), serum glycosylated hemoglobin (HbA1c), serum lipid levels, albuminuria (microalbuminuria, macroalbuminuria), diabetes with/without CVD complications (primary and secondary groups), cardiovascular risk factors (hypertension, hyperlipidemia, albuminuria, current smoking, family history of CVD), and aspirin usage.

**Data collection**

Data for this study were collected and recorded in data extraction form using Microsoft Excel\textsuperscript{®} 2013. Medical records of patients who were diagnosed with non-insulin-dependent diabetes mellitus (ICD-10 code with E11 computerized from outpatient hospital data) were reviewed since 2013. Retrospective analysis was conducted on medical history, aspirin prescription, side effects and contraindications. Lab investigation results were recorded based on recent blood tests.

**Data analysis**

Statistical analyses were performed using Stata Corp 2013. Demographic and baseline characteristics of all participants as discrete data are represented in percentage values and continuous data are represented in arithmetic mean with standard deviation (S.D.) and corresponding 95% confidence interval (CI). Subgroup differences were evaluated using on Likelihood-ratio,
chi-squared tests, Pearson’s chi-squared test or Fisher’s exact test. Statistical significance was p-value<0.05. Prevalence of aspirin use in both primary and secondary groups was calculated with corresponding 95% CI.

**Ethical considerations**

The study protocol was approved by the Ethics Committee, Faculty of Medicine, Prince of Songkla University.

**Results**

**Baseline characteristics of diabetic patients**

The number of diabetic patients who were followed up at outpatient clinics at Songkla Hospital from 1st–31st December 2013 was 1,342 patients. Diabetes was more commonly found in female patients (55.3%) than in male patients (44.7%). Mean age was 64.3 years old. Most patients had government health insurance coverage (62.3%). Nearly half of the patients received treatment at the internal medicine clinic (52.5%). The mean bodyweight and BMI were 66.9 kg and 26.3 kg/m² respectively. Most patients fell in the obese group (50.5%). Mean blood pressure was 139.6/76.4 mmHg. Two-thirds of patients took anti-diabetic medications (77.9%). The other drugs that most diabetic patients used were NSAIDs (15.7%). Mean lipid profile, FBS, and HbA1c are shown in Table 1.

**Types of diabetic patients (prevention group)**

Types of prevention groups consisted of the primary prevention group (diabetic patients without a history of coronary heart disease, cerebrovascular disease or peripheral vascular disease) comprising 1,078 patients (80.3%), (95% CI=78.1–82.4) and the secondary prevention group (diabetic patients with history of coronary heart disease, cerebrovascular disease or peripheral vascular disease) which had 264 patients (19.7%), (95% CI=17.5–21.8).

**Table 1** Baseline characteristics of diabetic patients

| Characteristics                              | Mean or percentage (n=1,342) (%) | Standard deviation | 95% confidence interval |
|----------------------------------------------|----------------------------------|--------------------|-------------------------|
| Age (year)                                   | 64.3                             | 11.5               | 63.7–64.9               |
| Sex                                           |                                  |                    |                         |
| Men                                           | 44.7                             | –                  | 42.0–47.4               |
| Women                                         | 55.3                             | –                  | 52.5–57.9               |
| Health insurance                              |                                  |                    |                         |
| Social insurance                              | 3.9                              | –                  | 2.9–5.1                 |
| Universal health coverage service             | 15.1                             | –                  | 13.1–17.0               |
| Government                                    | 62.3                             | –                  | 59.6–64.8               |
| No insurance                                  | 12.2                             | –                  | 10.4–14.0               |
| Government enterprise                         | 2.7                              | –                  | 1.8–3.6                 |
| Local government                              | 3.8                              | –                  | 2.9–5.0                 |
Table 1 (continued)

| Characteristics                              | Mean or percentage (n=1,342) (%) | Standard deviation | 95% confidence interval |
|----------------------------------------------|----------------------------------|--------------------|-------------------------|
| Population per clinic                        |                                  |                    |                         |
| Internal med                                 | 52.5                             |                    | 49.7–55.1               |
| Endocrine med                                | 25.2                             |                    | 22.9–27.6               |
| Cardio med                                   | 3.4                              |                    | 2.4–4.4                 |
| GP                                           | 0.6                              |                    | 0.2–1.1                 |
| Surgery                                      | 0.1                              |                    | 0.0–0.4                 |
| PCU                                          | 18.3                             |                    | 16.2–20.4               |
| Bodyweight (kg)                              | 66.9                             | 12.8               | 66.1–67.5               |
| Body height (cm)                             | 159.4                            | 8.6                | 158.9–159.9             |
| BMI (kg/m²)                                  | 26.3                             | 4.2                | 26.0–26.5               |
| BMI group                                    |                                  |                    |                         |
| Underweight                                  | 0.9                              |                    | 0.6–1.9                 |
| Normal                                       | 17.4                             |                    | 18.1–22.9               |
| Overweight                                   | 16.2                             |                    | 16.8–21.4               |
| Obesity                                      | 50.5                             |                    | 56.4–62.1               |
| Blood pressure                               |                                  |                    |                         |
| Systolic BP (mmHg)                           | 139.6                            | 18.9               | 138.5–140.6             |
| Diastolic BP (mmHg)                          | 76.4                             | 12.8               | 75.7–77.1               |
| Lipid profile                                |                                  |                    |                         |
| Total cholesterol (mmol/L)                   | 177.6                            | 42.4               | 175.3–179.8             |
| Low density lipoprotein cholesterol (mmol/L)| 108.8                            | 36.7               | 106.7–110.7             |
| Triglyceride (mmol/L)                        | 147.5                            | 87.2               | 142.8–152.2             |
| High density lipoprotein cholesterol (mmol/L)| 50.9                             | 13.5               | 50.2–51.7               |
| Fasting blood sugar (mmol/L)                 | 155.3                            | 54.8               | 152.3–158.1             |
| HbA1c                                        | 8.0                              | 1.8                | 7.9–8.1                 |
| Treatment                                    |                                  |                    |                         |
| Life style                                   | 4.6                              |                    | 3.4–5.8                 |
| Oral med                                     | 77.9                             |                    | 75.5–80.0               |
| Oral med+Insulin                             | 10.9                             |                    | 9.3–12.7                |
| Insulin                                      | 6.6                              |                    | 5.3–8.0                 |
| Others drug                                  |                                  |                    |                         |
| Antiplatelet                                 | 4.4                              |                    | 3.3–5.6                 |
| Anticoagulant                                | 1.4                              |                    | 0.8–2.2                 |
| NSAIDs                                       | 15.7                             |                    | 13.7–17.7               |
| Steroids                                     | 3.4                              |                    | 2.5–4.5                 |

GP=general practice, PCU=primary care unit, BMI=body mass index, BP=blood pressure, HbA1c=hemoglobin A1c, NSAIDs=nonsteroidal anti-inflammatory drugs
In the primary prevention group dyslipidemia was a more common risk factor for cardiovascular disease than hypertension, albuminuria, current smoking and family history of CVD. According to the risks of cardiovascular disease in the primary prevention group, we found that the high risk group (10-year risk ≥10.0%) contained most patients in this group (71.5%). In the secondary group, we found that diabetic patients with a history of cardiovascular disease were the most common type. Results shown in Table 2.

Prevalence of aspirin prescription in diabetic patients

The prevalence of aspirin prescribed for type 2 diabetic patients in Songklanagarind Hospital was 425 patients (31.7%) which could be categorized as the primary prevention group: prevalence of aspirin prescription was 19.0% (n=205), (95 % CI=12.0–21.3). The department that most frequently prescribed aspirin for the primary prevention group was the endocrinology clinic (21.2%) and cardiology was the clinic that prescribed aspirin the least (15.4%). The highest risk factor for cardiovascular disease in diabetic patients who were prescribed aspirin was albuminuria (39.6%) and the lowest risk factor was family history of CVD (17.6%). When risk factors were subdivided into high, moderate and low according to the ten-year risk of cardiovascular disease in diabetic patients, we found that the high risk group (recommend low-dose aspirin) had the highest aspirin prescription rate (22.6%), the moderate risk group (prescribed aspirin according to clinical judgment) was 9.9% and the low risk group (aspirin should not be recommended for CVD prevention) was not prescribed aspirin. Results shown in Table 3. The secondary prevention group: Prevalence of aspirin prescription was 83.7% (n=220), (95% CI=78.6–87.9). The diabetic patients with a history of coronary

Table 2  Baseline characteristic of diabetic patients categorized by patient prevention group

| Characteristics                          | Mean of percentage (n=1,342) (%) | 95% confidence interval |
|------------------------------------------|---------------------------------|-------------------------|
| Primary prevention group variables (n=1,078) |                                 |                         |
| Diagnosis of hypertension                | 73.9                            | 71.5–76.3               |
| Diagnosis of dyslipidemia                | 85.6                            | 83.6–87.4               |
| Diagnosis of albuminuria                 | 23.9                            | 21.4–26.5               |
| Current smoking                          | 11.2                            | 8.1–14.9                |
| Family history of cardiovascular diseases | 88.2                            | 63.5–98.5               |
| Risk of CVD in primary prevention group  |                                 |                         |
| High risk                                | 71.5                            | 68.6–74.1               |
| Moderate risk                            | 27.1                            | 24.4–29.8               |
| Low risk                                 | 1.5                             | 0.8–2.4                 |
| Secondary prevention group variables (n=264) |                                 |                         |
| History of cardiovascular diseases        | 11.8                            | 10.0–13.6               |
| History of cerebrovascular disease       | 8.5                             | 7.0–10.1                |
| History of peripheral arterial disease    | 0.4                             | 0.1–0.9                 |
heart disease were prescribed aspirin the most (89.8%), patients with cerebrovascular disease were prescribed aspirin 80.7% of the time, and patients with a history of PAD were prescribed aspirin at a rate of 66.0%. According to the clinics in this group, we found that the Primary Care Unit prescribed aspirin more than the other clinics (87.5%) and the Endocrinology Clinic had the lowest aspirin prescription rate (80.4%). Results shown in Table 3.

**Table 3** Aspirin prescription among type 2 diabetic patients categorized by patient characteristics

| Patient characteristics                                      | Percentage | P-value |
|--------------------------------------------------------------|------------|---------|
| **Primary prevention group**                                 |            |         |
| Risk factor of cardiovascular disease                        |            |         |
| Diagnosis of hypertension                                    | 0.000<sup>a</sup> |         |
| Yes                                                          | 37.9       |         |
| No                                                           | 62.1       |         |
| Diagnosis of dyslipidemia                                    | 0.000<sup>a</sup> |         |
| Yes                                                          | 34.6       |         |
| No                                                           | 65.4       |         |
| Diagnosis of albuminuria                                     | 0.002<sup>a</sup> |         |
| Yes                                                          | 39.6       |         |
| No                                                           | 60.4       |         |
| Current smoking                                              | 0.015<sup>a</sup> |         |
| Yes                                                          | 35.0       |         |
| No                                                           | 65.0       |         |
| Family history of cardiovascular diseases                     | 0.875<sup>a</sup> |         |
| Yes                                                          | 17.6       |         |
| No                                                           | 82.4       |         |
| Ten–year cardiovascular risk                                 | 0.000<sup>a</sup> |         |
| Low                                                          | 0          |         |
| Moderate                                                     |            |         |
| Yes                                                          | 9.9        |         |
| No                                                           | 90.1       |         |
| High                                                         |            |         |
| Yes                                                          | 22.6       |         |
| No                                                           | 77.4       |         |

**Table 3** (continued)

| Patient characteristics                                      | Percentage | P-value |
|--------------------------------------------------------------|------------|---------|
| **Secondary prevention group**                               |            |         |
| History of coronary heart disease                            | 0.000<sup>a</sup> |         |
| Yes                                                          | 89.9       |         |
| No                                                           | 10.1       |         |
| History of peripheral arterial disease                       | 0.070<sup>a</sup> |         |
| Yes                                                          | 80.7       |         |
| No                                                           | 19.3       |         |
| History of cerebrovascular disease                           | 0.855<sup>a</sup> |         |
| Yes                                                          | 66.7       |         |
| No                                                           | 33.3       |         |

A= Pearson chi-squared test, B= Fisher’s exact test

**Prevalence of contraindications and side effects**

The contraindications of aspirin prescription in this study were severe liver disease (0.9%), history of recent GI bleeding (0.4%), history of recent intracranial bleeding (0.2%), bleeding disorders (0.2%) and active peptic ulcer 0.1%). Results shown in Table 4.

**Table 4** Contraindications of aspirin prescription

| Contraindication                                           | Percentage (n=1,342) % | 95% confidence interval |
|-----------------------------------------------------------|------------------------|-------------------------|
| Active peptic ulcer                                       | 0.1                    | 0.0–0.4                 |
| History of recent gastrointestinal bleeding               | 0.4                    | 0.1–0.9                 |
| History of recent intracranial bleeding                   | 0.2                    | 0.0–0.5                 |
| Bleeding disorders (such as thrombocytopenia, hemophilia, Von Willebrand disease) | 0.2 | 0.0–0.5 |
| Severe liver disease                                      | 0.9                    | 0.5–1.6                 |
The most common side effects of aspirin prescription found in this study were gastrointestinal such as gastrointestinal bleeding, GI upset, dyspepsia or gastritis (1.0%), followed by tinnitus (0.1%). Results shown in Table 5.

There was a positive correlation between age, HbA1c and the dose of prescribed aspirin (p-value< 0.001, 0.003 respectively). These patients were more likely to have their dose of aspirin increased as age and HbA1c increased. Results shown in Figure 1–2.

**Table 5** Side effect in case prescribed aspirin

| Side effect                  | Percentage (n=425) (%) | 95% confidence interval |
|------------------------------|------------------------|-------------------------|
| Not reported                 | 96.5                   | 95.4–99.1               |
| Gastrointestinal             | 1.0                    | 0.8–2.4                 |
| Neurological (tinnitus)      | 0.1                    | 0.0–0.6                 |

**Figure 1** Box plot shows correlation between age and dose of aspirin prescription

**Figure 2** Box plot shows correlation between HbA1c and dose of aspirin prescription
Discussion
This study is cross-sectional aimed at investigating the prevalence of aspirin prescriptions among type 2 diabetic patients who were followed up at outpatient clinics at Songklanagarind Hospital. The author was motivated to conduct the study because in Thailand there have been few studies on the topic. In this study, 31.7% of diabetic patients were prescribed aspirin. Although prescribing regular low-dose aspirin might reduce all-cause CVD and mortality in the primary prevention of type 2 diabetes, only 19.0% of patients in this study had total aspirin prescriptions. In the secondary prevention group, in which aspirin is reported to significantly decrease the risks of recurrent cardiovascular events the rate of aspirin prescription was found to be 83.7%. Both results of aspirin prescription are as low as studies conducted in Spain, Canada, Taiwan and the United Kingdom.\textsuperscript{10,17–19} where retrospective and observational data were collected in diabetic patients using the same techniques as this study. However these results are inconsistent with studies from the USA.\textsuperscript{11} It could be due to the fact that in the USA aspirin prescriptions for diabetic patients are recommended by ADA and AHA guidelines.\textsuperscript{8,9} Aspirin (75–162 mg/day) is recommended for primary prevention in adults with diabetes who have a high risk of cardiovascular disease (10-year risk $\geq$ 10%), but this study found that only 22.6% of total aspirin recommendations were prescribed. Therefore, physicians are recommended to consider the risks of developing cardiovascular complications in all diabetic patients: if there is a high risk for a cardiovascular event and no limitation to receiving aspirin, aspirin should be prescribed based on the guidelines.

Aspirin has many side effects such as the increased risk of GI bleeding, intracranial bleeding, tinnitus, hepatic transaminitis and hypersensitivity\textsuperscript{12–16} but this study found a very low rate of side effects, consistent with the contraindications too.

Data for this study were collected by computerizing the outpatient hospital data where some histories were insufficient causing a lack of accuracy in, for example, history of smoking, height, family history of CVD or side effects of aspirin and etc.

Conclusion
Despite the fact aspirin is a safe, inexpensive and readily available therapy that is effective in preventing cardiovascular disease in diabetic patients and likely to provide benefits rather than side effects and contraindications, the author found significant underuse of aspirin therapy, especially in the primary prevention of cardiovascular disease in diabetic patients. Aspirin should be prescribed more frequently by physicians in order to reduce the risk of cardiovascular disease in these patients.

Acknowledgement
The author is grateful to the Department of Family Medicine, Prince of Songkla University for its financial support. I would like to especially thank Mr. Kittisak Choomalee for helping with the statistical analysis. I would also like to thank all the staff of the Department of Family Medicine, Faculty of Medicine, Prince of Songkla University for their assistance.

References
1. Pratipanawatr T, Chetthakul T, Ngarmukos C, Leelawatana R, Plengvidhya N, Suwanwalaikom S, et al. Thailand diabetic registry cohort predicting death in Thai diabetic patients and causes of death. J Med Assoc Thai 2010; 93: 12 – 20.
2. McCulloch DK. Glycemic control and vascular complications in type 2 diabetes mellitus [homepage on the Internet]. Philadelphia: UpToDate; 2013 [cited 2013 Mar 20]. Available
from: http://www.uptodate.com/contents/glycemic-control–
and–vascular–complications–in–type–2
3. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardio–
vascular events in people with diabetes. Diabetes Care 2010; 33: 2694 – 700.
4. Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovascular and all–cause mortality in type 2 diabetes in a primary prevention setting: the fremantle diabetes study. Diabetes Care 2010; 33: 317 – 21.
5. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low–dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293 – 03.
6. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337 – 43.
7. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta–analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849 – 60.
8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2014; 37: 14 –1.
9. Michael P, Mark JA, John AC, Mary C, Silvio EI, Debarat M, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetessjournals 2010; 33: 1395 – 402.
10. Mainar AS, Artieda RN, Gutierrez JR, Bobadilla JF, Garrido XF, Riera RR. Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. BMC Family Practice 2007; 8: 1 – 8.
11. Shaun RM, Benjamin L, Charles DM. Prevalence of anti–platelet therapy in patients with diabetes. Cardiovas Diabetol 2005; 4: 1 – 7.
12. Edward SH, Lisa LS, Wendy WH, Salina SL, Andrew TC. Long–term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426 – 33.
13. Aspirin side effects [homepage on the Internet]. Drugs.com; 2013 [cited 2013 Mar 20]. Available from: http://www.drugs.
14. Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL. Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci 2003; 23: 3944 – 52.
15. Aspirin comprehensive prescribing information [homepage on the Internet]. New Jersey: Bayer Corporation; 2013 [cited 2013 Mar 10]. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/4012B1_03_Appd%201-Professional%20Labeling.pdf
16. Luis AG, Kueiyu JL, Sonia H, Saga J. Risk of upper gastrointestinal bleeding with low–dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. AHA journal 2011; 123: 1108 – 15.
17. Jennifer AK, Jeffrey AJ, Lisa MG, Ellen LT, Lee TK, Richard ZL, et al. Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Clin Ther 2004; 26: 439 – 46.
18. Fu CC, Yeh Ji, Lee YM, Pei D, Chang TK, Shaw CK, et al. Prevalence and associated factors of aspirin use among adults with diabetes in eastern Taiwan. Tzu Chi Med 2005; 17: 233 – 7.
19. Cull CA, Neil HA, Holman RR. Changing aspirin use in patients with type 2 diabetes in the UKPDS. Diabet Med 2004; 21: 1368 – 71.